6:116916217:TAC:T (rs762966411)

Nearest gene: RFX6

Most severe consequence: frameshift variant

AF 2.0e-3(ranges from 1.5e-3 to 2.2e-3 across all phenotypes)

AF in gnomAD genomes 2.1: FIN 2.9e-3, POPMAX ., FIN enrichment vs. NFEE: No NFEE in gnomAD

INFO 0.833 (ranges in genotyping batches from 0.572 to 1.000 )

Number of alt homozygotes: 1

View in Open Targets , gnomAD , UCSC , GWAS Catalog , dbSNP

p-values smaller than 1e-10 are shown on a log-log scale
I Certain infectious and parasitic diseases (AB1_)II Neoplasms from hospital discharges (CD2_)II Neoplasms, from cancer register (ICD-O-3)III Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D3_)IV Endocrine, nutritional and metabolic diseases (E4_)Diabetes endpointsV Mental and behavioural disorders (F5_)Alcohol related diseasesPsychiatric endpoints from Katri RäikkönenNeurological endpointsVI Diseases of the nervous system (G6_)VII Diseases of the eye and adnexa (H7_)VIII Diseases of the ear and mastoid process (H8_)Cardiometabolic endpointsIX Diseases of the circulatory system (I9_)X Diseases of the respiratory system (J10_)Asthma and related endpointsInterstitial lung disease endpointsCOPD and related endpointsXI Diseases of the digestive system (K11_)Dental endpointsGastrointestinal endpointsXII Diseases of the skin and subcutaneous tissue (L12_)Rheuma endpointsXIII Diseases of the musculoskeletal system and connective tissue (M13_)XIV Diseases of the genitourinary system (N14_)XV Pregnancy, childbirth and the puerperium (O15_)XVI Certain conditions originating in the perinatal period (P16_)XVII Congenital malformations, deformations and chromosomal abnormalities (Q17)XVIII Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R18_)XIX Injury, poisoning and certain other consequences of external causes (ST19_)XX External causes of morbidity and mortality (VWXY20_)XXI Factors influencing health status and contact with health services (Z21_)Drug purchase endpointsOperation endpointsDiseases marked as autimmune originDemonstration endpointsMiscellaneous, not yet classified endpointsOther, not yet classified endpoints (same as #MISC)Comorbidities of AsthmaComorbidities of Neurological endpointsComorbidities of COPDComorbidities of DiabetesComorbidities of Gastrointestinal endpointsComorbidities of Interstitial lung disease endpoints-log₁₀p-value024681016

3095 total codes
category phenotype beta (se) p-value -log10(p) af cases af controls number of samples UKBB UKBB N samples
IV Endocrine, nutritional and metabolic diseases (E4_) Type 2 diabetes 0.65 4.1e-15 14.4 2.9e-3 1.8e-3 49303 / 255466 NA NA
IV Endocrine, nutritional and metabolic diseases (E4_) Type 2 diabetes with other specified/multiple/unspecified complications 0.72 6.5e-15 14.2 3.0e-3 1.8e-3 35857 / 255466 NA NA
Diabetes endpoints Diabetes, insuline treatment (Kela reimbursement) (more control exclusions) 0.66 9.0e-15 14.0 3.0e-3 1.8e-3 41247 / 255500 NA NA
Diabetes endpoints Diabetes, varying definitions 0.61 1.0e-14 14.0 2.9e-3 1.8e-3 53388 / 255766 NA NA
IV Endocrine, nutritional and metabolic diseases (E4_) Diabetes mellitus 0.61 1.1e-14 13.9 2.9e-3 1.8e-3 53688 / 255466 NA NA
Diabetes endpoints Diabetes, insuline treatment (Kela reimbursement) 0.64 2.0e-14 13.7 3.0e-3 1.8e-3 41247 / 267907 NA NA
Diabetes endpoints Type 2 diabetes, definitions combined, including avohilmo 0.63 1.5e-13 12.8 2.8e-3 1.8e-3 46818 / 253665 NA NA
IV Endocrine, nutritional and metabolic diseases (E4_) Type 2 diabetes, strict (exclude DM1) 0.61 3.0e-12 11.5 2.8e-3 1.8e-3 44266 / 256217 NA NA
Diabetes endpoints Type 2 diabetes, wide definition 0.72 3.2e-12 11.5 3.0e-3 1.8e-3 28960 / 257444 NA NA
Diabetes endpoints Type 2 diabetes, definitions combined 0.61 3.3e-12 11.5 2.8e-3 1.8e-3 44313 / 255449 NA NA
Download table data as TSV